# FDA approves axatilimab-csfr for chronic graft-versus-host disease

Source: [What's New: Drugs RSS Feed](http://www.fda.gov/drugs/cancer-approvals/fda-approves-axatilimab-csfr-chronic-graft-versus-host-disease) · 2026-11-07 · Medicine
Page: https://themorning.science/story/fda-approves-axatilimab-csfr-for-chronic-graft-versus-host-disease-82c1a1a700c9651d
Kind: launch · Impact: medium

## In brief

- On August 14, 2024, the FDA approved axatilimab-csfr (Niktimvo, Incyte Corporation) for chronic graft-versus-host disease (cGVHD).
- The approval covers cGVHD patients who have failed at least two prior lines of systemic therapy.
- Axatilimab is a colony stimulating factor-1 receptor (CSF-1R)-blocking antibody.

## Why it matters

It adds a targeted antibody option for chronic GVHD, a serious complication after allogeneic stem cell transplantation, for patients whose earlier treatments have not worked.

## Timeline

- 2024-08-14: FDA approves axatilimab-csfr (Niktimvo) for chronic graft-versus-host disease

## Coverage

- [FDA approves axatilimab-csfr for chronic graft-versus-host disease](http://www.fda.gov/drugs/cancer-approvals/fda-approves-axatilimab-csfr-chronic-graft-versus-host-disease) — What's New: Drugs RSS Feed, 2026-11-07

Tags: fda approval, graft-versus-host disease, transplantation, monoclonal antibody, csf-1r, hematology

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science